Comparison of antithrombin activity assays in detection of patients with heparin binding site antithrombin deficiency: systematic review and meta-analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 10 2023
04 10 2023
Historique:
received:
26
06
2023
accepted:
30
09
2023
medline:
1
11
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
Antithrombin (AT) deficiency increases the risk for venous thromboembolism, therefore, a highly sensitive assay to identify this condition is crucial. The aim of this paper was to perform a meta-analysis comparing AT activities measured by different AT activity assays in patients with heparin binding site AT deficiency. In addition, the diagnostic sensitivity of selected assays was compared depending on the available data. An extensive literature search was performed considering results with publication date up to July 10, 2021. Seven relevant English-language observational studies, comparing AT activity measured by different AT activity assays in Caucasian Europeans with either the AT Budapest III or AT Padua I mutation were included in meta-analyses. There was no significant difference in AT activity between Labexpert and Innovance in patients with AT Budapest III (P = 0.567) and AT Padua I (P = 0.265), while AT activity determined by HemosIL was significantly higher compared to Innovance for both mutations (AT Budapest III: P < 0.001; AT Padua I: P < 0.001). These results are in line with the results of comparison of diagnostic sensitivity. In patients with AT Budapest III, the AT activity was also higher when measured with Berichrom compared to Innovance (P = 0.002), however, the results of comparison of diagnostic sensitivity across studies were variable. No significant difference (P = 0.117) in AT activity as well as diagnostic sensitivity was observed between Sta-Stachrom and Innovance. The results of our study suggest that Innovance, Labexpert and Sta-Stachrom are the most sensitive activity assays for detection of AT Budapest III and AT Padua I, whereas HemosIL showed considerably lower sensitivity for these two variants. As revealed in our study, the diagnostic sensitivity of AT activity assays to type II heparin binding site AT deficiency is different, and in some assays mutation dependent.
Identifiants
pubmed: 37794095
doi: 10.1038/s41598-023-43941-x
pii: 10.1038/s41598-023-43941-x
pmc: PMC10551003
doi:
Substances chimiques
Heparin
9005-49-6
Anticoagulants
0
Antithrombins
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16734Informations de copyright
© 2023. Springer Nature Limited.
Références
Hsu, E. & Moosavi, L. Biochemistry (StatPearls Publishing, 2021).
Bravo-Perez, C., Vicente, V. & Corral, J. Management of antithrombin deficiency: An update for clinicians. Expert Rev. Hematol. 12, 397–405 (2019).
pubmed: 31116611
doi: 10.1080/17474086.2019.1611424
Ishiguro, K. et al. Complete antithrombin deficiency in mice results in embryonic lethality. J. Clin. Investig. 106, 873–878 (2000).
pubmed: 11018075
pmcid: 517819
doi: 10.1172/JCI10489
Bravo-Perez, C. et al. Genotype-phenotype gradient of SERPINC1 variants in a single family reveals a severe compound antithrombin deficiency in a dead embryo. Br. J. Haematol. 191, e32–e35 (2020).
pubmed: 32686144
doi: 10.1111/bjh.16963
Sokol, J. et al. Mild antithrombin deficiency and risk of recurrent venous thromboembolism: Results from the MEGA follow-up study. J. Thromb. Haemost. 16, 680–688 (2018).
pubmed: 29377625
doi: 10.1111/jth.13960
Van Cott, E. M. et al. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH. J. Thromb. Haemost. 18, 17–22 (2020).
pubmed: 31894660
doi: 10.1111/jth.14648
Egeberg, O. Inherited antithrombin deficiency causing thrombophilia. Thromb. Diath Haemorrh. 13, 516–530 (1965).
pubmed: 14347873
Sas, G., Blasko, G., Banhegyi, D., Jako, J. & Palos, L. A. Abnormal antithrombin III (antithrombin III “Budapest”) as a cause of a familial thrombophilia. Thromb. Diath Haemorrh. 32, 105–115 (1974).
pubmed: 4454033
Stenson, P. D. et al. Human gene mutation database (HGMD): 2003 update. Hum. Mutat. 21, 577–581 (2003).
pubmed: 12754702
doi: 10.1002/humu.10212
Corral, J., de la Morena-Barrio, M. E. & Vicente, V. The genetics of antithrombin. Thromb. Res. 169, 23–29 (2018).
pubmed: 30005274
doi: 10.1016/j.thromres.2018.07.008
Alhenc-Gelas, M. et al. Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency. Thromb. Haemost. 117, 1040–1051 (2017).
pubmed: 28300866
doi: 10.1160/TH16-08-0635
Luxembourg, B. et al. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype in hereditary antithrombin deficiency. Thromb. Haemost. 111, 249–257 (2014).
pubmed: 24196373
Kovac, M. et al. Poor pregnancy outcome in women with homozygous type-II HBS antithrombin deficiency. Thromb. Res. 133, 1158–1160 (2014).
pubmed: 24702813
doi: 10.1016/j.thromres.2014.03.025
Bereczky, Z., Gindele, R., Speker, M. & Kallai, J. Deficiencies of the natural anticoagulants—Novel clinical laboratory aspects of thrombophilia testing. EJIFCC 27, 130–146 (2016).
pubmed: 27683526
pmcid: 4975229
Puurunen, M., Salo, P., Engelbarth, S., Javela, K. & Perola, M. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: Clinical picture. J. Thromb. Haemost. 11, 1844–1849 (2013).
pubmed: 23910795
doi: 10.1111/jth.12364
Sanchez, C., Alessi, M. C., Saut, N., Aillaud, M. F. & Morange, P. E. Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. J. Thromb. Haemost. 6, 1975–1977 (2008).
pubmed: 18761717
doi: 10.1111/j.1538-7836.2008.03144.x
Navarro-Fernandez, J. et al. Antithrombin Dublin (p.Val30Glu): A relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb. Haemost. 116, 146–154 (2016).
pubmed: 27098529
doi: 10.1160/TH15-11-0871
Orlando, C., Heylen, O., Lissens, W. & Jochmans, K. Antithrombin heparin binding site deficiency: A challenging diagnosis of a not so benign thrombophilia. Thromb. Res. 135, 1179–1185 (2015).
pubmed: 25837307
doi: 10.1016/j.thromres.2015.03.013
Javela, K., Engelbarth, S., Hiltunen, L., Mustonen, P. & Puurunen, M. Great discrepancy in antithrombin activity measured using five commercially available functional assays. Thromb. Res. 132, 132–137 (2013).
pubmed: 23768451
doi: 10.1016/j.thromres.2013.05.012
Kovacs, B. et al. The superiority of anti-FXa assay over anti-FIIa assay in detecting heparin-binding site antithrombin deficiency. Am. J. Clin. Pathol. 140, 675–679 (2013).
pubmed: 24124146
doi: 10.1309/AJCPVY4Z9XZMFOTH
Zeng, W. et al. Genetic analysis should be included in clinical practice when screening for antithrombin deficiency. Thromb. Haemost. 113, 262–271 (2015).
pubmed: 25298121
doi: 10.1160/TH14-05-0446
Muszbek, L., Bereczky, Z., Kovacs, B. & Komaromi, I. Antithrombin deficiency and its laboratory diagnosis. Clin. Chem. Lab. Med. 48(Suppl 1), S67–S78 (2010).
pubmed: 21062218
Gindele, R. et al. Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary: Phenotype analysis in a large cohort. J. Thromb. Haemost. 14, 704–715 (2016).
pubmed: 26748602
doi: 10.1111/jth.13252
Bereczky, Z. et al. Age and origin of the founder antithrombin Budapest 3 (p.Leu131Phe) mutation; its high prevalence in the Roma population and its association with cardiovascular diseases. Front. Cardiovasc. Med. 7, 617711 (2020).
pubmed: 33614741
doi: 10.3389/fcvm.2020.617711
Reda, S. et al. Functional characterization of antithrombin mutations by monitoring of thrombin inhibition kinetics. Int. J. Mol. Sci. 22, 2119 (2021).
pubmed: 33672736
pmcid: 7924598
doi: 10.3390/ijms22042119
Gindele, R. et al. Clinical and laboratory characteristics of antithrombin deficiencies: A large cohort study from a single diagnostic center. Thromb. Res. 160, 119–128 (2017).
pubmed: 29153735
doi: 10.1016/j.thromres.2017.10.023
Ruhl, H., Reda, S., Muller, J., Oldenburg, J. & Potzsch, B. Activated factor X-based versus thrombin-based antithrombin testing in thrombophilia workup in the DOAC era. Thromb. Haemost. 118, 381–387 (2018).
pubmed: 29378360
doi: 10.1160/TH17-08-0568
Kovac, M. et al. The influence of specific mutations in the AT gene (SERPINC1) on the type of pregnancy related complications. Thromb. Res. 173, 12–19 (2019).
pubmed: 30458337
doi: 10.1016/j.thromres.2018.11.006
Kovac, M. et al. Genotype phenotype correlation in a pediatric population with antithrombin deficiency. Eur. J. Pediatr. 178, 1471–1478 (2019).
pubmed: 31359133
doi: 10.1007/s00431-019-03433-5
Merz, M. et al. Clinical multicenter evaluation of a new FXa-based antithrombin assay. Int. J. Lab. Hematol. 33, 498–506 (2011).
pubmed: 21535419
doi: 10.1111/j.1751-553X.2011.01326.x
Olson, S. T., Richard, B., Izaguirre, G., Schedin-Weiss, S. & Gettins, P. G. Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. Biochimie 92, 1587–1596 (2010).
pubmed: 20685328
pmcid: 2974786
doi: 10.1016/j.biochi.2010.05.011
Gindele, R. et al. Investigation of the differences in antithrombin to heparin binding among antithrombin Budapest 3, Basel, and Padua mutations by biochemical and in silico methods. Biomolecules 11, 544 (2021).
pubmed: 33917853
pmcid: 8068293
doi: 10.3390/biom11040544
Hemker, H. C. A century of heparin: Past, present and future. J. Thromb. Haemost. 14, 2329–2338 (2016).
pubmed: 27862941
doi: 10.1111/jth.13555
Hemker, H. C., Al Dieri, R. & Beguin, S. Heparins: A shift of paradigm. Front. Med. 6, 254 (2019).
doi: 10.3389/fmed.2019.00254
Jeske, W. et al. Bovine mucosal heparins are comparable to porcine mucosal heparin at USP potency adjusted levels. Front. Med. 5, 360 (2018).
doi: 10.3389/fmed.2018.00360
Cooper, P. C., Coath, F. & Makris, M. The phenotypic and genetic assessment of antithrombin deficiency. Int. J. Lab. Hematol. 33, 227–237 (2011).
pubmed: 21401902
doi: 10.1111/j.1751-553X.2011.01307.x
Owen, M. C. et al. Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His. Blood 69, 1275–1279 (1987).
pubmed: 3567355
doi: 10.1182/blood.V69.5.1275.1275
Amin, H. et al. Coagulation factors and antithrombin levels in young and elderly subjects in Pakistani population. Blood Coagul. Fibrinol. 23, 745–750 (2012).
doi: 10.1097/MBC.0b013e328358e913
Khor, B. & Van Cott, E. M. Laboratory tests for antithrombin deficiency. Am. J. Hematol. 85, 947–950 (2010).
pubmed: 21108326
doi: 10.1002/ajh.21893
Croles, F. N., Mulder, R., Mulder, A. B., Lukens, M. V. & Meijer, K. β-Antithrombin, subtype of antithrombin deficiency and the risk of venous thromboembolism in hereditary antithrombin deficiency: A family cohort study. Thromb. Res. 168, 47–52 (2018).
pubmed: 29902631
doi: 10.1016/j.thromres.2018.06.004
Armstrong, M. Siemens Healthcare Launches Innovance Antithrombin Test in Europe. https://medtech.pharmaintelligence.informa.com/MT040950/Siemens-Healthcare-launches-Innovance-Antithrombin-test-in-Europe (2009).
Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, 71 (2021).
doi: 10.1136/bmj.n71
Joanna Briggs Institute. Critical Appraisal Tools for Use in JBI Systematic Reviews: Checklist for Analytical Cross Sectional Studies. http://joannabriggs.org/research/critical-appraisal-tools.html (2017).
Wan, X., Wang, W., Liu, J. & Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 14, 135 (2014).
pubmed: 25524443
pmcid: 4383202
doi: 10.1186/1471-2288-14-135
Schünemann, H., Brożek, J., Guyatt, G. & Oxman, A. GRADE Handbook: Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. https://gdt.gradepro.org/app/handbook/handbook.html (The GRADE Working Group, 2013)